Preview

Obstetrics, Gynecology and Reproduction

Advanced search

POSSIBILITY OF APPLICATION OF MAGNESIUM SULFATE AS A NEUROPROTECTOR IN THE DEVELOPMENT OF PREMATURE BIRTH

Full Text:

Abstract

The paper presents the data of meta-analyses and individual randomized studies on the effectiveness of magnesium sulfate as a drug to reduce the risk of cerebral palsy in the development of premature birth.

About the Authors

I. O. Makarov
GBOU VPO “First Moscow state medical university named after I.M. Sechenov” of Ministry of Healthcare of Russia
Russian Federation


E. I. Borovkova
GBOU VPO “First Moscow state medical university named after I.M. Sechenov” of Ministry of Healthcare of Russia
Russian Federation


References

1. American College of Obstetricians and Gynecologists Committee on Obstetric Practice, Society for Maternal-Fetal Medicine. Committee Opinion No. 455: Magnesium sulfate before anticipated preterm birth for neuroprotection. Obstet. Gynecol. 2010; 115: 669.

2. Altman D., Carroli G., Duley L. et al. Do women with pre-eclampsia, and their babies, benefit from magnesium sulphate? The Magpie Trial: a randomised placebo-controlled trial. Lancet 2002; 359: 1877.

3. Costantine M.M., Weiner S.J., Eunice Kennedy Shriver. Effects of antenatal exposure to magnesium sulfate on neuroprotection and mortality in preterm infants: a meta-analysis. ObstetGynecol 2009; 114: 354.

4. Crowther C.A., Hiller J.E., Doyle L.W. et al. Effect of magnesium sulfate given for neuroprotection before preterm birth: a randomized controlled trial. JAMA 2003; 290: 2669.

5. Doyle L.W., Crowther C.A., Middleton P., Marret S. Antenatal magnesium sulfate and neurologic outcome in preterm infants: a systematic review. Obstet. Gynecol. 2009; 113: 1327.

6. Doyle L.W., Crowther C.A., Middleton P. et al. Magnesium sulphate for women at risk of preterm birth for neuroprotection of the fetus. Cochrane Database Syst. Rev. 2009; CD004661.

7. Moster D., Lie R.T., Markestad T. Long-term medical and social consequences of preterm birth. N. Engl. J. Med. 2008; 359: 262.

8. Marret S., Doyle L.W., Crowther C.A., Middleton P. Antenatal magnesium sulphateneuroprotection in the preterm infant. Semin Fetal Neonatal Med 2007; 12:311.

9. Marret S., Marpeau L., Follet-Bouhamed C. et al. Effect of magnesium sulphate on mortality and neurologic morbidity of the very-preterm newborn (of less than 33 weeks) with two-year neurological outcome: results of the prospective PREMAG trial. Gynecol. Obstet. Fertil. 2008; 36: 278.

10. Nelson K.B., Grether J.K. Can magnesium sulfate reduce the risk of cerebral palsy in very low birthweight infants? Pediatrics 1995; 95: 263.

11. Prevalence and characteristics of children with cerebral palsy in Europe. Dev Med Child Neurol 2002; 44: 633.

12. Pryde P.G., Mittendorf R. Contemporary usage of obstetric magnesium sulfate: indication, contraindication, and relevance of dose. Obstet. Gynecol. 2009; 114: 669.

13. Rouse D.J., Hirtz D.G., Thom E. et al. A randomized, controlled trial of magnesium sulfate for the prevention of cerebral palsy. N. Engl. J. Med. 2008; 359: 895.

14. Saigal S., Doyle L.W. An overview of mortality and sequelae of preterm birth from infancy to adulthood. Lancet. 2008; 371: 261.

15. The Antenatal Magnesium Sulphate for Neuroprotection Guideline Development Panel. Antenatal magnesium sulphate prior to preterm birth for neuroprotection of the fetus, infant and child: National clinical practice guidelines. Adelaide: The University of Adelaide. 2010.

16. Yeargin-Allsopp M., Van Naarden Braun K., Doernberg N.S. et al. Prevalence of cerebral palsy in 8-year-old children in three areas of the United States in 2002: a multisite collaboration. Pediatrics 2008; 121: 547.


For citation:


Makarov I.O., Borovkova E.I. POSSIBILITY OF APPLICATION OF MAGNESIUM SULFATE AS A NEUROPROTECTOR IN THE DEVELOPMENT OF PREMATURE BIRTH. Obstetrics, Gynecology and Reproduction. 2013;7(1):41-44. (In Russ.)

Views: 102


ISSN 2313-7347 (Print)
ISSN 2500-3194 (Online)